Navigation Links
Transgenomic to Present at the Rodman & Renshaw 12th Annual Global Investment Conference
Date:9/8/2010

OMAHA, Neb., Sept. 8 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) today announced that Craig Tuttle, president and chief executive officer, will deliver the Company's corporate presentation at the Rodman & Renshaw 12th Annual Global Investment Conference on Monday, September 13 at 4:55 p.m. EDT.  The conference will be held at the Palace Hotel in New York City from September 13th – 15th, 2010.

The presentation will be webcast live at http://www.wsw.com/webcast/rrshq18/tbio and is available for viewing at the Company's web site at www.transgenomic.com where it will also be archived for 90 days following the event.

Mr. Tuttle will be available for one-on-one meetings with investors participating in the Rodman & Renshaw Global Investment Conference. For those who would like to schedule an appointment with Transgenomic management, please contact Kim Golodetz, Lippert/Heilshorn & Associates, Inc., at 212-838-3777 or at kgolodetz@lhai.com or contact your Rodman & Renshaw representative.

About Transgenomic, Inc.  

Transgenomic, Inc. (www.transgenomic.com) is a global biotechnology company specializing in high sensitivity genetic variation and mutation analysis, providing products and services in DNA mutation detection and discovery for clinical research, clinical molecular diagnostics and pharmacogenomics analyses. Its product offerings include the WAVE® Systems and associated consumables specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification. With broad applicability to genetic research, nearly 1,500 systems have been shipped to customers in more than 50 countries. The SURVEYOR® Mutation Detection Kits and SURVEYOR Check-It Kit provide reagents and protocols for high sensitivity detection of mutations in DNA. In addition, HANABI automated chromosome harvesting systems improve laboratory productivity with consistent quality compared with manual methods for cytogenetic analyses. Service offerings include the Transgenomic Molecular Laboratory, which provides reference laboratory services specializing in molecular diagnostics including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology and Inherited Diseases. Transgenomic Pharmacogenomics Services is a CRO for pharmacogenomic, translational research and clinical trials.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.


'/>"/>
SOURCE Transgenomic, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
2. Transgenomic Establishes Collaboration With the National Cancer Institute to Investigate Mitochondrial Genome and Associated Nuclear Genes in Cancer Cell Lines
3. Transgenomic and Power3 Medical Complete Agreement for Exclusive License of Neurodegenerative Biomarker Test
4. Transgenomic Signs Exclusive License for Cold-PCR Technology From the Dana-Farber Cancer Institute
5. Webcast Alert: Transgenomic Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast
6. Reminder Webcast Alert: Transgenomic, Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast
7. Transgenomic, Inc. Executes License Option agreement for Parkinsons Disease Diagnostic Markers with Gene Solutions, LLC
8. Transgenomic Demonstrates Very High Sensitivity Detection of Tumor-Associated KRAS Mutations in Matched Plasma Samples Using COLD-PCR
9. Transgenomic Reports Fourth Quarter Financial Results
10. Transgenomic to Present at the Noble Financial Sixth Annual Equity Conference - ONTRACK 2010
11. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... -- Since its commercial introduction in 2005, ... science tool for conducting genetic studies in a range ... its new report that the industry sits on the ... a range of new applications in the clinical diagnostics ... ) , Since the Human Genome ...
(Date:5/25/2016)... -- According to a new market research ... by Therapeutic Area (Oncology, Cosmeceutical/Plastic Surgery), by Application (Drug ... Hospitals/ Clinics) - Forecast to 2021", published by MarketsandMarkets, ... the forecast period of 2016 to 2021. This market ... from USD 117.3 Million in 2016, at a CAGR ...
(Date:5/25/2016)... , Germany and ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ... a licensing and co-development agreement with Therawis Diagnostics GmbH to ... will be to develop and market PITX2 as a marker ... other high-risk breast cancer patients. "We are pleased ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... 31, 2016 , ... The University of Tennessee Medical Center ... the latest in Clinical Patient Pod (CPP) technologies provided through Jvion’s ... into the clinical workflow. These insights are empowering the more than 30 case ...
(Date:5/31/2016)... Calif. (PRWEB) , ... May 31, 2016 , ... Effective ... colleagues, clients, and the industry as a whole. On June 2, Northbound CEO Mike ... on Addictive Disorders (WCSAD) and presenting the opening plenary on “Leadership: The Journey to ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... ... planetary and numeral energies can describe personality traits in humans. Using presidential candidate ... behind their name and vitality. , “AstroNumerology is not about adding numbers ...
(Date:5/31/2016)... ... ... TeaZa® Energy, LLC announces the launch of a new limited ... . The new flavor—Tropical TeaZa? Energy—will be available to customers exclusively online starting ... flavor is best described as a juicy, taste bud takeover. A mouthwatering wave ...
(Date:5/31/2016)... ... May 31, 2016 , ... To ... solutions to the healthcare industry, The University of Scranton is adding a Certificate ... path to a career in rapidly growing field of healthcare information. , ...
Breaking Medicine News(10 mins):